This study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption.

This prospective, non-randomized, open-label study assessed the effect of a nutrition support product on quality of life in adults with compromised gut function and malabsorption. Adults with irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) or celiac disease were enrolled in the study and asked to take the study product for 6 weeks. The primary measure of the study was a validated quality of life questionnaire, the Gastrointestinal Quality of Life Index (GIQLI). Secondary measures included the Inflammatory Bowel Disease Questionnaire (IBDQ), the Celiac Disease Questionnaire (CDQ), and the Digestive Symptom Frequency Questionnaire (DSFQ).

Inclusion Criteria:

• Body mass index 19 - 40 kg/m2
• Previous diagnosis of ulcerative colitis (UC), Crohn's disease, irritable bowel syndrome (IBS), or celiac disease

Exclusion Criteria:

• Gastroenterologic surgery within 3 months before the study period
• Have a colostomy or ileostomy bag
• Malignancy within the last 5 years
• Women who are lactating, pregnant or planning pregnancy during the study period
• Taking antibiotic, antiparasitic, or antifungal medications
• Initiation of or changes to supplements or medications within 28 days prior to screening